Tag:
Marijn Dekkers
Latest Headlines
Latest Headlines
FDA review backs Xarelto for big new use in ACS patients
The anticoagulant won a thumbs-up from FDA reviewers ahead of Wednesday's advisory panel meeting, where FDA experts will weigh a lucrative new indication.
Rumors put Bayer, Onyx at the M&A altar
With the Watson Pharmaceuticals-Actavis deal wrapped up, M&A hounds need something new to sniff out. And voilá!
Bayer eyes 16% pharma growth on new meds
Bayer CEO Marijn Dekkers is touting Xarelto 's multibillion-dollar prospects again. This time, though, it's just one of four prospective blockbusters drawing Dekkers' praise.
Bayer CEO Dekkers says price cuts threaten R&D
Bayer CEO Marijn Dekkers totted up a $2.7 billion price tag to research and develop the new anticoagulant Xarelto . And he's warning tight-fisted payers that the more they squeeze drug companies...
Bayer CEO: Shortsighted price cuts lead to long-term pain
Bayer chief Marijn Dekkers ( photo ) doesn't mind government interference of a sort. When he moved to Germany from the U.S., he found a strong focus on keeping jobs in Germany. "The system in most
Bayer predicts blockbuster success for four of its late-stage drugs
You can count Bayer among the Big Pharma companies unwilling to back down from their multibillion-dollar gambles on drug research. The company boldly predicted that four of its late-stage programs
Bayer bracing for profit-margin drop
Bayer 's profit margins are dropping as a result of the European debt crisis. The German drug giant is responding as any cautious drug company would--by stocking up on cash, Reuters is reporting.
Bayer chief aims for 37% pharma growth in China
Bayer CEO Marijn Dekkers ( photo ) likes to talk about his company's new anti-clotting drug Xarelto , and every time he mentions the brand, he seems more optimistic about it. He also likes to talk about
Dekkers uses tennis lessons at Bayer's helm
We're beginning to think pharma boards have one screening question for CEO candidates: Did you ever engage in competitive sports? Recent executive profiles have told us Novartis ( $NVS ) CEO Joe
Is a Bayer 'merger of equals' in the stars?
Bayer CEO Marijn Dekkers ( photo ) isn't desperate to make a match. But if the right company came along? Well, he might just do a deal. In an interview with Bloomberg, Dekkers said he'd like to bolster
